RGD肽与雌激素或雄激素缀合:激素替代治疗中增强抗骨质疏松效力并减轻不良反应的策略

被引：4

作者：

王文敬

李春玉

赵明

机构：

[1] 首都医科大学化学生物学与药学院

来源：

转化医学研究(电子版) | 2012年 / 2卷 / 02期

关键词：

骨质疏松症; 替补治疗; RGD-四肽; RGD-八肽; 雌激素; 雄激素; 缀合;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

骨质疏松症是老年女性和接受糖皮质激素及雄性激素阻断性治疗(androgen deprivation therapy,ADT)的患者主要的健康问题。激素替代治疗一直成功地用于预防老年女性和接受糖皮质激素及ADT的患者发生骨质疏松症。可是一旦把激素的剂量相关的不良反应,例如把激素的剂量相关的子宫内膜增生和血栓形成风险考虑进来,那么人们对激素替代治疗的长期疗效就会提出质疑。为了改善激素替代治疗,人们付出了大量努力。在这些卓有成效的工作中,RGD-肽与雌激素或雄激素缀合确实提高了激素替代治疗的疗效,并降低了激素替代治疗的不良反应。本文综述了RGD-肽与雌激素或雄激素形成的缀合物对激素替代治疗的贡献。

引用

页码：57 / 80

页数：24

共 18 条

[1]

3D QSAR of novel estrogen–RGD peptide conjugates: Getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.[J].Ming Zhao;Jiangyuan Liu;Xiaoyi Zhang;Li Peng;Chunyu Li;Shiqi Peng.Bioorganic & Medicinal Chemistry.2009, 10

[2]

Estrogen receptor subtype-specific effects on markers of bone homeostasis.[J].T. Hertrampf;B. Schleipen;M. Velders;U. Laudenbach;K.H. Fritzemeier;P. Diel.Molecular and Cellular Endocrinology.2008, 1

[3]

Pharmacogenetics of hormone replacement therapy for climacteric symptoms [J].

Takeo, Chikari ;

Ugai, Kanako ;

Araki, Jungo ;

Zhang, Ling ;

Baba, Masanori ;

Ohashi, Wataru ;

Ueno, Koichi ;

Suzuki, Yoichi ;

Amano, Keiko ;

Hirai, Aizan ;

Muramatsu, Masaaki .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (04) :604-608

[4]

Incidences of breast cancer throughout long-term hormone replacement therapy.[J].J. Cortés-Prieto;P. Juez-Martel.Journal of Steroid Biochemistry and Molecular Biology.2007, 3

[5]

Postmenopausal HRT and tibolone in relation to muscle strength and body composition [J].

Jacobsen, D. E. ;

Samson, M. M. ;

Kezic, S. ;

Verhaar, H. J. J. .

MATURITAS, 2007, 58 (01) :7-18

[6]

The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo [J].

Kwee, S. H. ;

Tan, H. H. ;

Marsman, A. ;

Wauters, C. .

MATURITAS, 2007, 58 (01) :83-90

[7]

Expression of osteoblast marker genes in rat calvarial osteoblast-like cells, and effects of the endocrine disrupters diphenylolpropane, benzophenone-3, resveratrol and silymarin [J].

Ziolkowska, Agnieska ;

Rucinski, Marcin ;

Pucher, Andrzej ;

Tortorella, Cinzia ;

Nussdorfer, Gastone G. ;

Malendowicz, Ludwick K. .

CHEMICO-BIOLOGICAL INTERACTIONS, 2006, 164 (03) :147-156

[8]

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review [J].

Alibhai, Shabbir M. H. ;

Gogov, Sven ;

Allibhai, Zishan .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 (03) :201-215

[9]

How to evaluate the risk-benefit ratio of the low-dose hormone replacement therapy?.[J].Henri Rozenbaum.Journal of Steroid Biochemistry and Molecular Biology.2006, 1

[10]

Synthetic progestins used in HRT have different glucocorticoid agonist properties.[J].Dominique Koubovec;Katharina Ronacher;Elisabeth Stubsrud;Ann Louw;Janet Patricia Hapgood.Molecular and Cellular Endocrinology.2005, 1

← 1 2 →